Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case

Despite the high initial susceptibility of ovarian cancer (OC) to chemotherapy, the vast majority of patients with Stages III–IV of the disease have its recurrences. Chemotherapy is a main treatment for recurrent OC. In Russia, the rate of platinum-resistant recurrences after first-line chemotherapy is more than 50 %, which may be due to the high extent of a tumor process at the moment of diagnosis, to the low rate of optimal cytoreductive interventions, and to non-optimal treatment. Many oncologists refuse to treat patients with recurrent platinum-resistant OC since the existing Russian and foreign guidelines point to the low efficiency of current chemotherapy for this type of recurrences. At the same time, whether chemotherapy should be used to treat platinum-resistant recurrences must be decided by taking into account a set of clinical factors that along with the duration of a platinum-free interval are also predictors for the efficiency of chemotherapy. These predictors should include mainly the histological pattern of a tumor; an immediate response to previous lines of chemotherapy; the number of previously used anticancer drugs; a patient’s general condition; and her existing factors that can influence the tolerability of chemotherapy. This paper describes a clinical case of a long-term survival in an OC patient who has developed a platinum-resistant recurrence just after first-line chemotherapy. Incomplete cross-resistance of the tumor to other drugs when a platinum-resistance recurrence develops, as well as its high susceptibility to the re-use of platinum-resistant derivatives possibly due to the artificial increase of a platinum-free interval should be identified among the factors that have influenced the prediction of treatment in this patient.

1. http://globocan.iarc.fr.

2. Злокачественные новообразования в России в 2012 г. Заболеваемость и смертность. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014. 250 с. [Malignant neoplasms in Russia in 2012. Morbidity and mortality. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2014. 250 p. (In Russ.)].

3. Тюляндин С.А., Покатаев И.А., Тюляндина А.С. и др. Лечение распространенного рака яичников: итоги работы отделения клинической фармакологии и химиотерапии РОНЦ им. Н.Н. Блохина РАМН за 1993–2010 гг. Вестник РАМН 2011;(12):4–9. [Tyulyandin S.A., Pokataev I.A., Tyulyandina A.S. et al. Management of advanced ovarian cancer: work results of Department of Clinical Pharmacology and Chemotherapy of N.N. Blokhin Russian Cancer Research Center at RAMS for 1993– 2010. Vestnik RAMN = Herald of RAMS 2011;(12):4–9. (In Russ.)].

4. Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2013;24 Suppl 6:vi24–32.

5. Markman M., Reichman B., Hakes T. еt al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9(10):1801–5.

6. Pokataev I., Tryakin A., Tjulandina A. et al. A phase II nonrandomized study of oxaliplatin/doxorubicin combination therapy in the treatment of recurrent ovarian cancer. Clin Ovarian Gynecol Cancer 2014; 6(1–2):11–6.

7. du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 rospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115(6):1234–44.

8. http://www.rosoncoweb.ru/standarts/RUSSCO/08.pdf.

9. Mackay H.J., Brady M.F., Oza A.M. et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20(6):945–52.

10. Faul C., Gerszten K., Edwards R. et al. A phase I/II study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Karnofsky score determines treatment outcome. Int J Radiat Oncol Biol Phys 2000;47(3): 749–54.

11. Monk B.J., Herzog T.J., Kaye S.B. et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28(19):3107–14.

12. Gordon A.N., Tonda M., Sun S. et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95(1):1–8.

13. Smith D.H., Adams J.R., Johnston S.R. et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002;13(10):1590–7.

14. O’Byrne K.J., Bliss P., Graham J.D. et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002;21:203a.

15. ten Bokkel Huinink W., Lane S.R., Ross G.A.; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15(1):100–3.

16. Ferrandina G., Ludovisi M., Lorusso D. et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26(6):890–6.

17. Mutch D.G., Orlando M., Goss T. et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25(19):2811–8.

18. Horowitz N.S., Hua J., Gibb R.K. et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004;94(1):67–73.

19. Kaye S.B., Colombo N., Monk B.J. et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011;22(1):49–58.

20. Rustin G.J., van der Burg M.E., Griffin C.L. et al.; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomised trial. Lancet 2010;376(9747): 1155–63.